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i.org/1recommended. Whether outcomes can be improved when follow-up is done by cardiologists
is uncertain. We aimed to determine the association between cardiology follow-up and risk
of death for patients with HF discharged from hospital. Using data from the National Heart
Failure Audit (England and Wales), we investigated the effect of referral to cardiology
follow-up on 30-day and 1-year mortality in 68,772 patients with HF and a reduced left
ventricular ejection fraction discharged from 185 hospitals from 2007 to 2013. The primary
analyses used instrumental variable analysis complemented by hierarchical logistic and
propensity-matched models. At the hospital level, rates of referral to cardiologists varied
from 6% to 96%. The median odds ratio (OR) for referral to cardiologist was 2.3 (95%
conﬁdence interval [CI] 2.1 to 2.5), suggesting that, on average, the odds of a patient being
referred for cardiologist follow-up after discharge differed w2.3 times from one randomly
selected hospital to another one. Based on the proportion of patients (per region) referred
for cardiology follow-up, referral for cardiology follow-up was associated with lower 30-day
(OR 0.70; 95% CI 0.55 to 0.89) and 1-year mortality (OR 0.81; 95% CI 0.68 to 0.95)
compared with no plans for cardiology follow-up (i.e., standard follow-up done by family
doctors). Results from hierarchical logistic models and propensity-matched models were
consistent (30-day mortality OR 0.66; 95% CI 0.61 to 0.72 and 0.66; 95% CI 0.58 to 0.76 for
hierarchical and propensity matched models, respectively). For patients with HF and a
reduced left ventricular ejection fraction admitted to hospital with worsening symptoms,
referral to cardiology services for follow-up after discharge is strongly associated with
reduced mortality, both early and late.  2016 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
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0.1016/j.amjcard.2016.10.021component. We sought to assess this policy recommendation
by investigating the effect of referral to cardiology follow-up
on the risk of 30-day and 1-year mortality in a large cohort of
patients admitted for heart failure and a reduced left ven-
tricular ejection fraction (HFREF) in England and Wales.
Methods
This study is a part of the Understanding National Vari-
ation and Effects of Interventions at different Levels of Care
for Heart Failure (UNVEIL-CHF) study, which aims to
characterize variation in care and outcomes for patients
hospitalized for heart failure (HF) from 2007 to 2013 and
enrolled in the National Heart Failure Audit for England and
Wales.1 Only hospital admissions in which the patient sur-
vived to discharge were eligible for inclusion in the study.
We restricted our analysis to patients with HFREF (an
ejection fraction <40% or evidence of left ventricular
systolic dysfunction) because clearly deﬁned and evidence-
based treatment recommendations exist only for this
subgroup of patients with HF. For patients with >1 hospitalccess article
4.0/).
www.ajconline.org
Table 1
Selected baseline characteristics by referral for cardiologist follow-up
Overall Cohort Propensity Matched Cohort
Follow Up
(n ¼ 40,769)
No Follow Up
(n ¼ 28,003)
Standardized
Difference
Follow Up
(n ¼ 11571)
No Follow Up
(n ¼ 11571)
Standardized
Difference
Predicted one year mortality (HF severity)* 25.5% 32.0% 52.7% 28.2% 28.3% 0.8%
Age (years)
<60 17.9% 6.5% 35.5% 10.8% 11.0% 0.7%
60-80 52.9% 39.3% 27.6% 51.4% 50.5% 1.7%
>80 29.2% 54.2% 52.6% 37.8% 38.4% 1.3%
Women 32.4% 42.5% 21.0% 64.3% 64.4% 0.1%
NYHA Class
I 6.3% 6.6% 1.2% 6.5% 6.6% 0.2%
II 19.3% 16.8% 6.5% 18.4% 18.3% 0.2%
III 45.9% 44.5% 2.8% 45.2% 45.5% 0.6%
IV 28.6% 32.2% 7.9% 29.9% 29.7% 0.6%
Peripheral Oedema
None 31.1% 24.9% 13.7% 28.3% 28.1% 0.4%
Mild 26.3% 25.6% 1.6% 26.2% 25.9% 0.7%
Moderate 28.7% 32.5% 8.3% 30.2% 30.5% 0.7%
Severe 14.0% 17.0% 8.2% 15.3% 15.4% 0.4%
Diabetes mellitus 30.0% 29.4% 1.2% 31.0% 30.9% 0.1%
Hypertension 50.6% 51.8% 2.4% 51.3% 51.0% 0.7%
Coronary Heart Disease 51.4% 51.3% 0.4% 52.8% 52.6% 0.3%
Valve Disease 19.7% 18.4% 3.3% 18.9% 19.0% 0.3%
Baseline ECG
Atrial ﬁbrillation 36.9% 44.3% 15.3% 39.5% 39.9% 0.6%
Left bundle branch block 12.8% 11.5% 4.0% 12.2% 12.2% 0.1%
Previous Myocardial Infarction 2.2% 1.7% 4.1% 1.9% 2.0% 0.3%
Baseline ECHO
Diastolic dysfunction 1.1% 1.0% 0.6% 1.0% 1.0% 0.5%
Left ventricular hypertrophy 0.9% 1.3% 4.2% 1.0% 1.0% 0.4%
Valve disease 5.4% 6.1% 2.9% 5.7% 5.4% 1.0%
Treated on Cardiology Ward 70.4% 38.2% 68.3% 59.0% 59.0% 0.1%
Therapies
ACE/ARB 84.6% 73.6% 27.3% 81.2% 81.2% 0.2%
Beta-blocker 77.6% 64.2% 30% 73.1% 73.3% 0.6%
ACEI/ARB ¼ Angiotensin-converting enzyme inhibitor/Angiotensin-receptor blocker; ECG ¼ electrocardiogram; ECHO ¼ echocardiogram; HF ¼ heart
failure; NYHA ¼ New York Heart Association.
* Logistic regression, adjusted for age, sex, breathlessness, peripheral edema, history of diabetes, history of ischemic heart disease, history of hypertension,
history of valve disease, atrial ﬁbrillation, left bundle branch block, previous myocardial infarction, diastolic dysfunction, left ventricular hypertrophy and valve
disease, used to predict the likelihood of death within one year.
2 The American Journal of Cardiology (www.ajconline.org)admission (10,280, 14.4%), we randomly selected 1
admission. Our exposure was referral for cardiology follow-
up after discharge from the hospital. Follow-up started from
the date of discharge and was censored at death or the end of
follow-up (March 2013). Two primary outcomes,
30-day and 1-year mortality, were used. As longer term
(>6 months) follow-up was not available for subjects
admitted in 2012/2013, the analyses of 1-year mortality was
restricted to 2007 to 2011. The analyses of 30-day mortality
were from 2007 until March 2013.
Because ﬁndings from nonrandomized comparisons are
commonly subject to confounding, our primary analysis was
based on a quasi-randomized design using an instrumental
variable approach.2 A valid instrument is correlated with the
treatment of interest (referral to cardiology follow-up) but is
not correlated with the outcome of interest (30-day and
1-year mortality), except through the treatment of interest.3
We, thus, used regional variation in referral to cardiology
follow-up, that is, the proportion of patients referred forcardiology follow-up in a given region, as our instrumental
variable. The instrument was validated by classifying
regions into ﬁfths, to examine whether prognostic factors
related to mortality are similar across regions and to
demonstrate that it is unlikely that regional variation in
cardiology referral would affect mortality other than through
difference in rates of referral to cardiology follow-up.2 Two-
stage least-square logistic regression with robust SEs was
then used to estimate the causal effect of referral for cardi-
ology follow-up on 30-day and 1-year mortality.
In addition, we conducted 2 complementary statistical
techniques to ensure that ﬁndings from our main analysis are
robust to our design and modeling assumptions.4 First,
hierarchical logistic models were used to examine the asso-
ciation between referral to cardiology follow-up and risk of
30-day and 1-year mortality, adjusting for 34 covariates: age,
gender, New York Heart Association class I, II, III, or IV,
peripheral edema (none, mild, moderate, or severe), history
of diabetes, history of ischemic heart disease, history of
Table 2
Selected patient characteristics across the ﬁfths of cardiology referral for follow-up at regional levels
Quintile of Regional Referral to Cardiology Follow Up Rates
Q1
(4.6-43.7)
Q2
(43.7-54.3)
Q3
(54.7-63.7)
Q4
(64.2-74.0)
Q5
(75.0-100)
Number of patients* 13539 13444 13977 13351 14461
Cardiology Referral Rate 34.4% 49.2% 59.1% 69.2% 83.0%
Predicted one year mortality (HF severity) 29.4% 28.7% 28.1% 27.5% 26.8%
Age (years)
<60 10.4% 12.0% 13.4% 14.5% 15.9%
60-80 45.4% 45.8% 47.0% 48.1% 50.3%
>80 44.2% 42.2% 39.6% 37.4% 33.8%
Women 39.1% 37.1% 36.9% 35.5% 34.0%
NYHA Class
I 8.1% 7.0% 6.2% 5.5% 5.2%
II 16.4% 17.4% 18.0% 19.1% 20.3%
III 42.6% 44.3% 46.5% 47.8% 45.5%
IV 32.9% 31.3% 29.3% 27.6% 29.0%
Peripheral Edema
None 28.8% 29.3% 28.3% 27.9% 28.6%
Mild 24.1% 25.4% 26.2% 27.2% 26.9%
Moderate 30.6% 29.9% 30.2% 30.1% 30.2%
Severe 16.5% 15.4% 15.3% 14.8% 14.3%
Diabetes mellitus 27.6% 29.2% 29.8% 30.7% 31.3%
Hypertension 48.2% 50.1% 51.5% 53.2% 52.5%
Coronary heart disease 48.9% 50.7% 51.2% 52.8% 53.1%
Valve disease 18.8% 19.6% 18.8% 19.0% 19.8%
Baseline ECG
Atrial ﬁbrillation 41.5% 40.5% 40.3% 39.4% 38.0%
Left bundle branch block 12.0% 12.9% 12.7% 12.4% 11.6%
Previous myocardial infarction 1.7% 1.7% 1.9% 2.3% 2.5%
Baseline ECHO
Diastolic dysfunction 0.7% 1.1% 1.1% 1.2% 1.1%
Left ventricular hypertrophy 1.0% 1.3% 1.1% 1.0% 0.8%
Valve disease 5.9% 6.6% 5.9% 5.6% 4.6%
Treated on Cardiology Ward 49.8% 54.2% 56.1% 56.1% 66.9%
Therapies
ACE-I/ARB 78.6% 79.4% 79.9% 81.1% 81.8%
Beta-blocker 69.7% 70.7% 71.4% 73.2% 75.5%
ACEI/ARB ¼ Angiotensin-converting enzyme inhibitor/Angiotensin-receptor blocker; ECG ¼ electrocardiogram; ECHO ¼ echocardiogram; HF ¼ heart
failure; NYHA ¼ New York Heart Association.
* Rounded to nearest number from multiply imputed estimates.
Heart Failure/Specialist Follow-up in Heart Failure 3hypertension, history of valve disease, atrial ﬁbrillation, left
bundle branch block, previous myocardial infarction, dia-
stolic dysfunction, left ventricular hypertrophy and valve
disease, prescription of ACE inhibitors/ARBs, aldosterone
receptor antagonists, loop diuretics, thiazide diuretics, b
blockers, digoxin, referral for HF specialist nurse follow-up,
referral for palliative care follow-up, referral for geriatric
follow-up, treatment on a cardiology ward, and dummy
variables for year of admission (2007, 2008, 2009, 2010,
2011, 2012, and 2013). Second, propensity score matching
was used to restrict any analysis to patients who were
similarly likely to be referred to cardiology follow-up.
Logistic regression was used to generate a propensity score
for each patient being referred for cardiology follow-up. In
total, 100 covariates were included in the logistic regression
model: the same 34 baseline covariates as mentioned earlier
and interaction terms between age, gender, and all covariates
excluding age and gender. Patients referred for cardi-
ology follow-up were then matched one-to-one withoutreplacement with subjects who were not referred for cardi-
ology follow-up. The effectiveness of the matching process
was gauged by examining the post-matching balance on
covariates. Hierarchical logistic regression was performed on
the matched sample, adjusting for all 34 covariates. Multiple
imputation with chained equations was used to impute
missing data; 5 imputations were generated. No covariate or
outcome was missing at a rate exceeding 15%.
Study ﬁndings are reported in accordance with the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) recommendations.5 No ethics
approval was needed for this analysis; the National Heart
Failure Audit was conducted with the approval of the NHS
Information Center.
Results
Overall, 68,772 patients with HFREF discharged from
185 hospitals were included in the analyses. At the hospital
Table 3
Association between type of follow up and thirty day and one year mortality
30-day Mortality One Year Mortality
Odds Ratio (95%
CI)
p-value Odds Ratio
(95% CI)
p-value
Cardiology Follow Up vs. No Cardiology Follow Up
Multivariable adjusted 0.66 (CI 0.61, 0.72) p <0.001 0.74 (CI 0.70, 0.78) p <0.001
Propensity score matched 0.66 (CI 0.58, 0.76) p<0.001 0.74 (CI 0.67, 0.82) p¼0.002
Instrumental variable estimated 0.70 (CI 0.55, 0.89) p¼0.005 0.81 (CI 0.68, 0.95) p¼0.012
All models adjusted for 34 demographic, clinical and therapy variables. Age, gender, NYHA breathlessness, level of peripheral oedema, history of diabetes,
history of hypertension, history of ischemic heart disease, history of valve disease, atrial ﬁbrillation, left bundle branch block, evidence of myocardial infarction
on baseline ECG, treatment in cardiology ward, treatment with aldosterone receptor antagonists, treatment with ACE inhibitors or ARB, treatment with beta
blockers, treatment with digoxin, treatment with thiazide diuretics, treatment with loop diuretics, referral for specialist HF nurse follow up, referral for care of
the elderly follow up, referral for palliative care follow up and baseline year of discharge. Propensity matched estimate is adjusted for the same variables, but
matched on the interaction of all thirty variables with sex and age, in addition to the thirty covariates adjusted for.
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Figure 1. Risk of death adjusted (survival curves are plotted at the mean of
each covariate using Cox regression) for 34 covariates and stratiﬁed by
referral to cardiology follow-up.
4 The American Journal of Cardiology (www.ajconline.org)level, rates of referral to cardiologists varied from 6% to
96%. The median odds ratio (OR) for referral to cardiologist
was 2.3 (95% conﬁdence interval [CI] 2.1 to 2.5), sug-
gesting that, on average, the odds of a patient being referred
for cardiologist follow-up after discharge differed w2.3
times from 1 randomly selected hospital to another one.
Hospitals that were tertiary hospitals and that had greater
numbers of consultant cardiologists had higher rates of
referral to cardiology follow-up (Supplementary Table 1).
The predicted mortality for patients referred for cardiol-
ogy follow-up was lower than those not referred for follow-
up (26% vs 32%, Table 1). Patients referred for cardiology
follow-up tended to be younger and more likely to be
prescribed ACE inhibitors/angiotensin receptor blockers and
b blockers at discharge (Table 1). Furthermore, patients
referred for cardiology follow-up were more likely to be
treated on a cardiology ward (70% of those referred for
follow-up vs 38% of those not referred) (Table 1).
For the instrumental variable analysis, we ﬁrst tested the
validity of the instrument. The proportion of patients
referred for cardiology follow-up varied signiﬁcantly across
regions, from 5% to 100% of patients. When regions were
divided into ﬁfths by proportion of patients referred for
cardiology follow-up, patient characteristics were broadly
similar (Table 2). Predicted 1-year mortality varied slightly
across regions, ranging from 29% to 27% from the lowest to
highest quintile of referral, although this difference was
similar to previous analyses that used regional variation.2
When regional proportion of patients referred for cardi-
ology follow-up was used as an instrument, referral for
cardiology follow-up was signiﬁcantly associated with
lower 30-day (OR 0.70 95% CI 0.55 to 0.89) and reduced 1-
year mortality (OR 0.81 95% CI 0.68 to 0.95, Table 3).
In hierarchical analysis, after adjustment, referral for car-
diology follow-up was associated with a substantially lower
risk of 30-day mortality (OR 0.66 95% CI 0.61 to 0.72) and
1-year mortality (OR 0.74 95% CI 0.70 to 0.78, Figure 1).
After propensity score matching, 11,571 patients with HF
referred for cardiology follow-up were matched to 11,571
patients with HF not referred for cardiology follow-up;
45,630 patients were excluded. Predicted 1-year mortality
was very similar between patients who were and were not
referred for cardiology follow-up (28% vs 28%, standardizeddifference of 0.8%), as was age, gender, breathlessness, and
medical history (all standardized differences <2%, Table 1).
After adjustment for 34 covariates on the matched sample,
referral for cardiology follow-up was still associated with a
substantially lower 30-day (OR 0.66 95% CI 0.58 to 0.76)
and 1-year mortality (OR 0.74 95% CI 0.67 to 0.82). Esti-
mates were similar when propensity score was also included
in the model (data not shown).
Instrumental variable estimation of the association
between referral for cardiology follow-up and 1-year mor-
tality was not substantially different if early deaths were
excluded (OR 0.84 95% CI 0.71 to 0.99, Table 4), although
this did attenuate the effect on 30-day mortality (OR 0.84
95% CI 0.64 to 1.11), suggesting a very early impact of
specialist care.
Discussion
We investigated the effect of the policy recommendation
that patients with HFREF should have care by specialist
cardiology services after discharge from hospital. Using
instrumental variable method, which exploits natural
random allocation of patients to a certain exposure variable
(in this case referral for cardiology follow-up by small
geographic regions), we show that referral to specialist
Table 4
Association between type of follow up and thirty day and one year mortality after exclusion of deaths in the ﬁrst seven days
Cardiology Follow Up vs. No Cardiology Follow Up 30-day Mortality One Year Mortality
Odds Ratio p-value Odds Ratio p-value
Multivariable adjusted 0.70 (CI 0.63, 0.77) p <0.001 0.75 (CI 0.71, 0.79) p <0.001
Propensity score matched* 0.69 (CI 0.60, 0.81) p <0.001 0.76 (CI 0.68, 0.85) p <0.001
Instrumental variable estimated 0.84 (CI 0.64, 1.11) p¼0.226 0.84 (CI 0.71, 0.99) 0.034
All models adjusted for 34 demographic, clinical and therapy variables. age, gender, NYHA breathlessness, level of peripheral oedema, history of diabetes,
history of hypertension, history of ischemic heart disease, history of valve disease, atrial ﬁbrillation, left bundle blockers, evidence of myocardial infarction on
baseline ecg, treatment in cardiology ward, treatment with aldosterone receptor antagonists, treatment with ACE inhibitors or ARB, treatment with beta
blockers, treatment with digoxin, treatment with thiazide diuretics, treatment with loop diuretics, referral for specialist HF nurse follow up, referral for care of
the elderly follow up, referral for palliative care follow up and baseline year of discharge. Propensity matched estimate is adjusted for the same variables, but
matched on the interaction of all thirty variables with sex and age, in addition to the thirty covariates adjusted for. Instrumental variable estimate utilizes
proportion of patients referred for cardiology follow up in 3360 regions.
* Non hierarchical logistic model used due to a lack of convergence with the hierarchical model. Standard errors instead adjusted for clustering at the hospital
level.
Heart Failure/Specialist Follow-up in Heart Failure 5cardiology services is strongly associated with lower risk of
death after discharge. In this large national linked database,
arrangement of a follow-up appointment after discharge
with a cardiologist was associated with a 30% lower odds of
death at 30 days after discharge (OR 0.70, 95% CI 0.55 to
0.89) and a 19% lower odds at 1 year after discharge (OR
0.81, 95% CI 0.68 to 0.95). These ﬁndings were robust to
alternative statistical modeling techniques and assumptions.
To our knowledge, this is the ﬁrst study to demonstrate
that referral for cardiology follow-up soon after discharge
with HF is associated with a substantial reduction in mor-
tality. This has important implications for policy and prac-
tice to improve outcomes. As suggested in an earlier report,
interventions to tackle the low referral rates after discharge
could also contribute to reductions in between-hospital
variation in quality of care.6
However, there are several potential limitations to our
ﬁndings. First, we only examined the association of cardiology
follow-up with mortality in HF with reduced ejection fraction
as there are few recommended therapeutic interventions for
HF with preserved ejection. Second, our analysis relied on
retrospective registry data, which may contain recording errors
of patients’ diagnoses. Third, our instrumental variables anal-
ysis was not powered to examine the association of referral to
cardiology follow-up with mortality in subgroups. Conse-
quently the effect of cardiology follow-up on outcomes in
certain subgroups of patients with HF, such as those who are
New York Heart Association class I, may differ from the effect
of cardiology follow-up in the overall HFREF population.
Despite our rigorous design and analytical approach, we
cannot entirely rule out that some of the association observed
is because of unmeasured confounding factors. Policy in-
terventions can be costly and a formal cost-effectiveness
analysis might also be needed to guide decision makers
about the costs and consequences of cardiology follow-up. In
this context, future studies should also address the impact of
the intervention on other important outcomes such as
re-hospitalization.
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